Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 7/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288218 | 0.91 | HDAC3 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL287752 | 0.87 | PIK3C3 (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL287756 | 0.86 | PIK3CD (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL287817 | 0.85 | CYP2C9 (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL287544 | 0.85 | MEN1 (0.45) | HDAC3HDAC11HDAC8HDAC6BDKRB1 | |
| SCHEMBL288105 | 0.84 | CYP3A4 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL24037777 | 0.84 | DYRK1A (0.34) | HDAC3HDAC2GCKLMNA | |
| SCHEMBL287839 | 0.83 | BRAF (0.51) | BRAF | |
| SCHEMBL287795 | 0.83 | HTT (0.45) | ALDH1A1TP53BRAFLMNA | |
| SCHEMBL288124 | 0.81 | PIK3CD (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | claimed |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-11-09 | — | — | US | claimed |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-03-02 | — | — | US | claimed |
| EP-2170830-B1 | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS | PLEXXIKON INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2010-07-29 | — | — | US | disclosed |
| EP-2170830-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009012283-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012283-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HDAC3 1716/4885HDAC4 1163/4885HDAC1 850/4885 |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HDAC3 1716/4885HDAC4 1163/4885HDAC1 850/4885 |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K11, MAP3K10 | HDAC3 1013/4885HDAC4 1289/4885HDAC1 457/4885 |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, MAP3K13, MAP3K8 | HDAC3 1716/4885HDAC4 1163/4885HDAC1 850/4885 |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HDAC3 1716/4885HDAC4 1163/4885HDAC1 850/4885 |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HDAC3 1716/4885HDAC4 1163/4885HDAC1 850/4885 |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HDAC3 1716/4885HDAC4 1163/4885HDAC1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.